Expanded Access Program (EAP) to Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib

The aim of this EAP is to make Daraxonrasib available to eligible patients with pancreatic adenocarcinoma, a serious & life-threatening condition, who have no comparable or satisfactory alternative therapy approved by the FDA.

For more information please visit https://clinicaltrials.gov/study/NCT07573215?cond=Pancreatic%20Cancer&intr=daraxonrasib&viewType=Card&rank=1

Interested in Volunteering for the Study?

If you would like more information about this study, please call us at 318-212-8671 .